Altimmune (ALT) News Today $7.55 -0.21 (-2.71%) (As of 05:19 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Altimmune, Inc. (NASDAQ:ALT) Shares Sold by State Street CorpState Street Corp decreased its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 12.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 3,413,827 shares of the company's stock after selling 495,459 shares duringDecember 24 at 3:32 AM | marketbeat.comAltimmune (NASDAQ:ALT) Stock Price Down 4.6% - Here's WhyAltimmune (NASDAQ:ALT) Shares Down 4.6% - Here's What HappenedDecember 23 at 2:05 PM | marketbeat.comB.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)December 21 at 2:42 AM | markets.businessinsider.comAltimmune, Inc: Altimmune Added to Nasdaq Biotechnology IndexDecember 19, 2024 | finanznachrichten.deAltimmune’s Nasdaq Biotech Index Addition Fuels Retail Enthusiasm, Stock ReboundsDecember 19, 2024 | msn.comWhy Altimmune Was Such a Robustly Healthy Stock on ThursdayDecember 19, 2024 | fool.comAltimmune (NASDAQ:ALT) Trading 4.7% Higher - Time to Buy?Altimmune (NASDAQ:ALT) Trading 4.7% Higher - Should You Buy?December 19, 2024 | marketbeat.comAltimmune Added to Nasdaq Biotechnology IndexDecember 19, 2024 | globenewswire.comLightning Round: Ford's warranty problems will come back to haunt it, says Jim CramerDecember 18, 2024 | msn.comAltimmune (NASDAQ:ALT) Stock Price Down 5.1% - Should You Sell?Altimmune (NASDAQ:ALT) Trading Down 5.1% - Time to Sell?December 17, 2024 | marketbeat.comAltimmune 2025: Redefining Obesity And MASH TreatmentDecember 16, 2024 | seekingalpha.comVirtu Financial LLC Invests $674,000 in Altimmune, Inc. (NASDAQ:ALT)Virtu Financial LLC purchased a new stake in Altimmune, Inc. (NASDAQ:ALT - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 109,759 shares of the company's stock, valued at approximately $67December 15, 2024 | marketbeat.comAltimmune (NASDAQ:ALT) Shares Up 4.9% - Should You Buy?Altimmune (NASDAQ:ALT) Shares Up 4.9% - Should You Buy?December 13, 2024 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned a consensus rating of "Moderate Buy" from the eight analysts that are covering the firm, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one hasDecember 13, 2024 | marketbeat.comPortolan Capital Management LLC Sells 579,266 Shares of Altimmune, Inc. (NASDAQ:ALT)Portolan Capital Management LLC lowered its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 90.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 60,976 shares of the company'sDecember 5, 2024 | marketbeat.comLooking At Altimmune's Recent Unusual Options ActivityDecember 4, 2024 | benzinga.comAltimmune CEO on what’s next for its experimental obesity drugDecember 3, 2024 | msn.comAltimmune, Inc. (NASDAQ:ALT) Stake Lifted by Bellevue Group AGBellevue Group AG increased its position in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 43.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 863,660 shares of the coDecember 1, 2024 | marketbeat.comAltimmune to Participate at Two Upcoming Investor ConferencesNovember 26, 2024 | globenewswire.comDo Redditors Think That Altimmune Inc. (ALT) Has a Big Upside Potential?November 21, 2024 | msn.comHC Wainwright Decreases Earnings Estimates for AltimmuneAltimmune, Inc. (NASDAQ:ALT - Free Report) - Research analysts at HC Wainwright reduced their FY2024 earnings per share estimates for Altimmune in a report released on Wednesday, November 13th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.28) per shareNovember 18, 2024 | marketbeat.comAltimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of "Moderate Buy" from BrokeragesShares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned an average recommendation of "Moderate Buy" from the eight analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given aNovember 18, 2024 | marketbeat.comAltimmune presents data on effect of pemvidutide on inflammatory lipidsNovember 15, 2024 | markets.businessinsider.comAltimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting® 2024November 15, 2024 | globenewswire.comWhat is B. Riley's Estimate for Altimmune FY2024 Earnings?Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at B. Riley lowered their FY2024 EPS estimates for shares of Altimmune in a research note issued on Wednesday, November 13th. B. Riley analyst M. Mamtani now anticipates that the company will post earnings per share of ($1.40) for tNovember 15, 2024 | marketbeat.comWhat is B. Riley's Estimate for Altimmune Q1 Earnings?Altimmune, Inc. (NASDAQ:ALT - Free Report) - Investment analysts at B. Riley issued their Q1 2025 earnings per share (EPS) estimates for shares of Altimmune in a report released on Wednesday, November 13th. B. Riley analyst M. Mamtani anticipates that the company will post earnings per share of (November 14, 2024 | marketbeat.comAltimmune's (ALT) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $12.00 target price on shares of Altimmune in a report on Thursday.November 14, 2024 | marketbeat.comAltimmune Third Quarter 2024 Earnings: Beats ExpectationsNovember 14, 2024 | finance.yahoo.comAltimmune provided key pipeline updates with Q3 report, says B. RileyNovember 14, 2024 | markets.businessinsider.comAltimmune call volume above normal and directionally bullishNovember 13, 2024 | markets.businessinsider.comAltimmune’s Pemvidutide Progress and Expansion: A Buy Recommendation by Patrick TrucchioNovember 13, 2024 | markets.businessinsider.comAltimmune’s pemvidutide looks differentiated among GLP-1s, says H.C. WainwrightNovember 13, 2024 | markets.businessinsider.comAltimmune: Pemvidutide As MASH Drug Could Provide Competitive EdgeNovember 13, 2024 | seekingalpha.comAltimmune's Pemvidutide Gains Momentum: Sizeable TAMs In Obesity And Liver HealthNovember 13, 2024 | seekingalpha.comAltimmune, Inc. (NASDAQ:ALT) Q3 2024 Earnings Call TranscriptNovember 13, 2024 | msn.comAltimmune Reports Q3 2024 Financial Results and Advances Drug PipelineNovember 13, 2024 | markets.businessinsider.comGSA Capital Partners LLP Has $2.09 Million Holdings in Altimmune, Inc. (NASDAQ:ALT)GSA Capital Partners LLP trimmed its stake in shares of Altimmune, Inc. (NASDAQ:ALT - Free Report) by 30.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 339,595 shares of the company's stock after seNovember 13, 2024 | marketbeat.comAltimmune Inc (ALT) Q3 2024 Earnings Call Highlights: Strategic FDA Alignment and Expanding ...November 13, 2024 | finance.yahoo.comAltimmune Stock Goes Parabolic Following Q3 Results As CEO Touts 2025 As ‘Transformational Year:’ Retail UpbeatNovember 12, 2024 | msn.comAltimmune, Inc: Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial OfficerNovember 12, 2024 | finanznachrichten.deAltimmune Announces Third Quarter 2024 Financial Results and Provides a Business UpdateNovember 12, 2024 | finance.yahoo.comAltimmune initiated with a Buy at UBSNovember 12, 2024 | markets.businessinsider.comAltimmune’s Pemvidutide: A Promising Buy Rating for Metabolic Health BreakthroughsNovember 12, 2024 | markets.businessinsider.comAltimmune Target of Unusually High Options Trading (NASDAQ:ALT)Altimmune, Inc. (NASDAQ:ALT - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 18,846 call options on the stock. This represents an increase of 185% compared to the typical daily volume of 6,618 call options.November 12, 2024 | marketbeat.comUBS Group Begins Coverage on Altimmune (NASDAQ:ALT)UBS Group began coverage on Altimmune in a research note on Tuesday. They issued a "buy" rating and a $26.00 price target on the stock.November 12, 2024 | marketbeat.comAltimmune announces inducement grants under Nasdaq listing ruleNovember 11, 2024 | markets.businessinsider.comAltimmune, Inc: Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | finanznachrichten.deAltimmune Names Greg Weaver Chief Financial OfficerNovember 11, 2024 | marketwatch.comAltimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial OfficerNovember 11, 2024 | globenewswire.comAltimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 11, 2024 | globenewswire.com Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address After New Years, price goes back up 4,800% (Ad)When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds for a dollar anymore! Click here to review Tim’s special Holiday offer before it’s too late. ALT Media Mentions By Week ALT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALT News Sentiment▼0.400.55▲Average Medical News Sentiment ALT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALT Articles This Week▼109▲ALT Articles Average Week Get Altimmune News Delivered to You Automatically Sign up to receive the latest news and ratings for ALT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDEAYA Biosciences News Apogee Therapeutics News CG Oncology News Tarsus Pharmaceuticals News Wave Life Sciences News Mirum Pharmaceuticals News Agios Pharmaceuticals News Harmony Biosciences News Akero Therapeutics News Recursion Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALT) was last updated on 12/24/2024 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredSix Stocks That Could Soar on Trump’s First Day BackThe recent election results have clarified a path forward, creating opportunities that weren't as clear just m...InvestorPlace | SponsoredTSLA *BANG* incoming (bullet in the chamber rn)I just pinpointed 5 dirt-cheap stocks that could soar the second the shot goes off. Thanks to Donald Trump’...StocksToTrade | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Altimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Altimmune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALT Stock Alerts